3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetic acid

3,4-dihydroxyphenylacetaldehyde has been researched along with 3,4-dihydroxyphenylacetic acid in 94 studies

Compound Research Comparison

Studies (3,4-dihydroxyphenylacetaldehyde)	Trials (3,4-dihydroxyphenylacetaldehyde)	Recent Studies (post-2010) (3,4-dihydroxyphenylacetaldehyde)	Studies (3,4-dihydroxyphenylacetic acid)	Trials (3,4-dihydroxyphenylacetic acid)	Recent Studies (post-2010) (3,4-dihydroxyphenylacetic acid)
99	0	50	5,410	38	591

Protein Interaction Comparison

Protein	Taxonomy	3,4-dihydroxyphenylacetaldehyde (IC50)	3,4-dihydroxyphenylacetic acid (IC50)
intestinal alkaline phosphatase precursor	Mus musculus (house mouse)		4.17

Research

Studies (94)

Timeframe	Studies, this research(%)	All Research%
pre-1990	15 (15.96)	18.7374
1990's	5 (5.32)	18.2507
2000's	22 (23.40)	29.6817
2010's	41 (43.62)	24.3611
2020's	11 (11.70)	2.80

Authors

Authors	Studies
Deitrich, RA; Tank, AW; Weiner, H	1
Mårdh, G; Vallee, BL	1
Deitrich, RA; Palmer, MR; Tottmar, O	1
Sharman, DF	1
Helander, A; Tottmar, O	3
Yu, PH	1
Nilsson, GE	1
Tottmar, O	1
MacKerell, AD; Pietruszko, R	1
Ferencz-Biro, K; MacKerell, AD; Pietruszko, R	1
Tank, AW; Thurman, JA; Weiner, H	1
Agarwal, DP; Goedde, HW; Harada, S	1
Chung, HD; Hsu, FF; Mattammal, MB; Strong, R	1
Chung, HD; Haring, JH; Mattammal, MB; Raghu, G; Strong, R	1
Bonuccelli, U; Colzi, A; Corsini, GU; Fornai, F; Iuliano, A; Musolino, A	1
Bamberg, H; Böhme, V; Moser, A; Scholz, J	1
Burke, WJ; Chung, HD; Li, SW	1
Eisenhofer, G; Harvey-White, J; Hayakawa, Y; Kirk, K; Kopin, IJ; Lamensdorf, I	1
Eisenhofer, G; Harvey-White, J; Kirk, K; Kopin, IJ; Lamensdorf, I; Nechustan, A	1
Brown, AM; Burke, WJ; Conway, AD; Jain, JC; Kristal, BS; Li, SW; Ulluci, PA	1
Keung, WM	1
Burke, WJ; Li, SW; Lin, TS; Minteer, S	1
Conti, G; Fornai, F; Gesi, M; Ruffoli, R; Santinami, A	1
Hashimoto, T; Yabe-Nishimura, C	1
Fan, J; Hayakawa, Y; Kirk, KL; Narayanan, J	1
Burke, WJ	1
FELLMAN, JH	1
Burke, WJ; Li, SW; Nonneman, R; Williams, EA; Zahm, DS	1
Burke, WJ; Chung, HD; Franko, M; Johnson, EM; Kristal, BS; Kumar, VB; Lampe, P; Li, SW; Ruggiero, DA; Williams, EA; Zahm, DS	1
Bonnet, JJ; Costentin, J; Dourmap, N; Janin, F; Legros, H	2
Bonnet, JJ; Costentin, J; Dingeval, MG; Janin, F; Legros, H	1
Galvin, JE	1
Anderson, DG; Brogden, NK; Doorn, JA; Florang, VR; Hurley, TD; Rees, JN	1
Deitrich, RA; Marchitti, SA; Vasiliou, V	1
Bustamante, D; Herrera-Marschitz, M; Israel, Y; Quintanilla, ME; Tampier, L	1
Anderson, DG; Doorn, JA; Florang, VR; Rees, JN	1
Anderson, DG; Doorn, JA; Florang, VR; Jinsmaa, Y; Rees, JN; Strack, S	1
Doorn, JA; Eckert, LL; Florang, VR; Rees, JN	1
Bertoldi, M; Voltattorni, CB	1
Goldstein, DS; Heredia-Moya, J; Holmes, C; Whittaker, N	1
Basile, MJ; Goldstein, DS; Holmes, C; Kopin, IJ; Mash, DC; Sullivan, P	1
Burke, WJ; Galvin, JE; Gan, Q; Kumar, VB; Panneton, WM	1
Christensen, BM; Erickson, SM; Han, Q; Harich, K; Huang, Y; Li, J; Vavricka, C	1
Doorn, JA; Florang, VR; Mexas, LM	1
Anderson, DG; Buettner, GR; Doorn, JA; Mariappan, SV	1
Barwina, M; Kaletha, K; Rybakowska, I; Sein Anand, J; Szreder, G; Waldman, W	1
Beausoleil, E; Kong, D; Kotraiah, V; Pallares, D; Toema, D	1
Fernandez, E; Goldstein, DS; Martinez, PA; Strong, R; Sullivan, P; Wey, MC	1
Doorn, JA; Florang, VR; Vermeer, LM	1
Cooney, A; Goldstein, DS; Gross, DJ; Holmes, C; Jinsmaa, Y; Kopin, IJ; Sharabi, Y; Sullivan, P; Sullivan, R	1
Barnhill, L; Bronstein, JM; Casida, JE; Cockburn, M; Fitzmaurice, AG; Lam, HA; Lulla, A; Maidment, NT; Murphy, NP; O'Donnell, KC; Rhodes, SL; Ritz, B; Sagasti, A; Stahl, MC	1
Alter, S; Goldstein, DS; Holmes, C; Kopin, IJ; Mash, DC; Miller, GW; Sharabi, Y; Strong, R; Sullivan, P	1
Cooney, A; Goldstein, DS; Gross, D; Jinsmaa, Y; Sharabi, Y; Sullivan, P	1
Goldstein, DS; Kopin, IJ; Sharabi, Y	1
Casida, JE; Cooney, A; Ford, B; Goldstein, DS; Jinsmaa, Y; Sullivan, P	1
Cooney, A; Goldstein, DS; Jinsmaa, Y; Sharabi, Y; Sullivan, P	1
Goldstein, DS; Holmes, C; Kopin, IJ; Mash, DC; Sharabi, Y; Sullivan, P	1
Araujo, GD; Coelho-Cerqueira, E; Domont, GB; Eliezer, D; Follmer, C; Pinheiro, AS; Yatabe-Franco, DY	1
Goldstein, DS; Holmes, C; Jinsmaa, Y; Kopin, IJ; Sharabi, Y; Sullivan, P	2
Bubacco, L; Plotegher, N	1
Goldstein, DS; Jinsmaa, Y; Sharabi, Y; Sullivan, P	1
Bax, A; DuMond, JF; Levine, RL; Werner-Allen, JW	1
Anderson, DG; Buettner, GR; Doorn, JA; Florang, VR; Schamp, JH	1
Berti, G; Bisaglia, M; Bubacco, L; Casella, L; Dalla Serra, M; Ferrari, E; Girotto, S; Greggio, E; Lunelli, L; Perego, C; Plotegher, N; Tessari, I; Veronesi, M; Zanetti, M	1
Bax, A; Levine, RL; Werner-Allen, JW	1
Baranyi, M; Gagov, H; Kalfin, R; Petkova-Kirova, P; Rakovska, A; Windisch, K	1
Diwakar, S; Melethadathil, N; Nair, B; Sasidharakurup, H	1
Aguirre, AL; Doorn, JA; Florang, VR; Murry, DJ; Vanle, BC	1
Goldstein, DS; Sharabi, Y	1
Han, Q; Li, J; Liang, J; Liao, C; Upadhyay, A	1
Bellen, HJ; Chen, R; D'Amelio, M; Gibbs, RA; Goldstein, DS; Graham, BH; Landrock, KK; Martini-Stoica, H; Stoica, G; Sullivan, P; Yamamoto, S	1
Doorn, JA; Enayah, SH; Fuortes, LJ; Ludewig, G; Vanle, BC	1
Bax, A; DuMond, JF; Levine, RL; Monti, S; Werner-Allen, JW	1
Goldstein, DS; Isonaka, R; Jinsmaa, Y; Sharabi, Y; Sullivan, P	1
Anderson, EJ; Builta, ZJ; Doorn, JA; Monroe, TB; Nelson, MM	1
do Nascimento, LA; Eliezer, D; Follmer, C; Lima, VA	1
Burke, WJ; Gillespie, KN; Hsu, FF; Kumar, VB; Lakshmi, VM	1
Agari, K; Araki, M; Hasunuma, T; Ishii, J; Kiyota, H; Kondo, A; Kuriya, Y; Li, J; Minami, H; Ogawa, T; Ono, F; Takahashi, S; Tsuge, K; Vavricka, CJ; Yoshida, T	1
Goldstein, DS; Isonaka, R; Jinsmaa, Y; Sharabi, Y	1
Goldstein, DS	2
Bellen, HJ; Duraine, L; Goldstein, DS; Kao, CY; Lee, HJ; Lin, SC; Tsai, MJ; Tsai, SY; Wang, L; Xu, M	1
Li, Y; Lu, Y; Pan, H; Shi, F; Wu, K; Yang, F	1
Cui, CP; Feng, Y; Gao, S; He, C; Li, BY; Li, KX; Qiao, GF; Sun, J; Sun, X; Wang, HD; Wang, X; Xiong, X; Yan, QX; Yin, RX; Zha, RR	1
Bermejo, MK; Dunn, AR; Fu, R; Goldstein, DS; Gregersen, E; Jensen, PH; Masoud, ST; Miller, GW; Nazari, R; Ramsey, A; Salahpour, A; Sullivan, P; Urs, NM; Vecchio, LM	1
Acquasaliente, L; Bucciantini, M; Fongaro, B; Leri, M; Palazzi, L; Polverino de Laureto, P; Stefani, M	1
Bowman, KR; Cagle, BS; Crawford, RA; Doorn, JA	1
Anderson, EJ; Crawford, RA; Doorn, JA; Gilardoni, E; Monroe, TB; Regazzoni, L	1
Ito, S; Ojika, M; Sugumaran, M; Tanaka, H; Wakamatsu, K	1

Reviews

12 review(s) available for 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetic acid

Article	Year
Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties). Pharmacology & toxicology, 2001, Volume: 89, Issue:5 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidation-Reduction; Species Specificity; Substantia Nigra	2001
3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease. Current drug targets. CNS and neurological disorders, 2003, Volume: 2, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Drug Delivery Systems; Humans; Neuroprotective Agents; Parkinson Disease	2003
Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology, 2004, Volume: 25, Issue:1-2 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Animals; Apoptosis; Catecholamines; Catechols; Humans; Neurodegenerative Diseases	2004
Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta neuropathologica, 2006, Volume: 112, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Dopamine; Humans; Oxidative Stress; Parkinson Disease; Substantia Nigra	2006
Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacological reviews, 2007, Volume: 59, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Aldehyde Dehydrogenase; Aldehyde Reductase; Aldehydes; Animals; Apoptosis; Arylsulfotransferase; Biological Transport; Brain; Catechol O-Methyltransferase; Catechols; Free Radicals; Glucuronosyltransferase; Humans; Neurons	2007
[Reactive oxygen species and 3,4-dihydroxyphenylacetaldehyde in pathogenesis of Parkinson disease]. Przeglad lekarski, 2011, Volume: 68, Issue:8 Topics: 3,4-Dihydroxyphenylacetic Acid; Brain; Humans; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species	2011
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacology & therapeutics, 2014, Volume: 144, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Apoptosis; Catecholamines; Humans; Lipid Peroxidation; Neurodegenerative Diseases; Neurons; Oxidation-Reduction; Parkinson Disease	2014
Lysines, Achilles' heel in alpha-synuclein conversion to a deadly neuronal endotoxin. Ageing research reviews, 2016, Volume: 26 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; alpha-Synuclein; Brain; Dopamine; Humans; Lysine; Metabolism; Neurodegenerative Diseases; Neurons	2016
The heart of PD: Lewy body diseases as neurocardiologic disorders. Brain research, 2019, 01-01, Volume: 1702 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Catecholamines; Dopamine; Heart; Humans; Lewy Bodies; Lewy Body Disease; Multiple System Atrophy; Myocardium; Neuroimaging; Neurons; Parkinson Disease; Sympathetic Nervous System	2019
3,4-Dihydroxyphenylacetaldehyde synthase and cuticle formation in insects. Developmental and comparative immunology, 2018, Volume: 83 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Humans; Insect Proteins; Insecta; Levodopa	2018
The catecholaldehyde hypothesis: where MAO fits in. Journal of neural transmission (Vienna, Austria : 1996), 2020, Volume: 127, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Dopamine; Humans; Monoamine Oxidase; Neurodegenerative Diseases; Neurons	2020
The "Sick-but-not-Dead" Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases. Seminars in neurology, 2020, Volume: 40, Issue:5 Topics: 3,4-Dihydroxyphenylacetic Acid; Autonomic Nervous System Diseases; Dopamine; Humans; Lewy Body Disease; Norepinephrine; Parkinson Disease; Sympathetic Nervous System	2020

Other Studies

82 other study(ies) available for 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetic acid

Article	Year
Effects of induction of rat liver cytosolic aldehyde dehydrogenase on the oxidation of biogenic aldehydes. Biochemical pharmacology, 1986, Dec-15, Volume: 35, Issue:24 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehydes; Animals; Cytosol; Dopamine; Enzyme Induction; Ethanol; Isoenzymes; Liver; Norepinephrine; Phenobarbital; Phenylethyl Alcohol; Polychlorinated Dibenzodioxins; Rats	1986
Human class I alcohol dehydrogenases catalyze the interconversion of alcohols and aldehydes in the metabolism of dopamine. Biochemistry, 1986, Nov-18, Volume: 25, Issue:23 Topics: 3-Methoxy-4-hydroxyphenylethanol; 3,4-Dihydroxyphenylacetic Acid; Acetaldehyde; Alcohol Dehydrogenase; Catechols; Dopamine; Ethanol; Humans; Isoenzymes; Kinetics; Liver; Phenylacetates; Phenylethyl Alcohol; Substrate Specificity	1986
Electrophysiological effects of monoamine-derived aldehydes on single neurons in neocortex and cerebellum in rats. Alcoholism, clinical and experimental research, 1986, Volume: 10, Issue:6 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebellum; Cerebral Cortex; Dopamine; Electrophysiology; Hydroxyindoleacetic Acid; Male; Neurons; Phenylacetates; Rats; Rats, Inbred Strains; Serotonin	1986
The metabolism of dopamine in the blood of ruminant animals: formation of 3,4-dihydroxyphenylacetaldehyde. Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology, 1987, Volume: 86, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biotransformation; Chromatography, High Pressure Liquid; Dopamine; Female; Monoamine Oxidase; Oxidation-Reduction; Phenylacetates; Phenylethyl Alcohol; Ruminants	1987
Metabolism of biogenic aldehydes in isolated human blood cells, platelets and in plasma. Biochemical pharmacology, 1987, Apr-01, Volume: 36, Issue:7 Topics: 3,4-Dihydroxyphenylacetic Acid; Blood Platelets; Drug Stability; Erythrocytes; Humans; Hydroxyindoleacetic Acid; In Vitro Techniques; Kinetics; Phenylacetates	1987
Effects of ethanol, acetaldehyde and disulfiram on the metabolism of biogenic aldehydes in isolated human blood cells and platelets. Biochemical pharmacology, 1987, Nov-15, Volume: 36, Issue:22 Topics: 3,4-Dihydroxyphenylacetic Acid; Acetaldehyde; Blood Platelets; Cells, Cultured; Disulfiram; Dopamine; Erythrocytes; Ethanol; Humans; Hydroxyindoleacetic Acid; Leukocytes; Phenylacetates; Phenylethyl Alcohol; Serotonin	1987
Metabolism of biogenic aldehydes in human blood: effects of ethanol, acetaldehyde and disulfiram. Alcohol and alcoholism (Oxford, Oxfordshire). Supplement, 1987, Volume: 1 Topics: 3,4-Dihydroxyphenylacetic Acid; Acetaldehyde; Aldehydes; Blood Platelets; Disulfiram; Erythrocytes; Ethanol; Humans; Hydroxyindoleacetic Acid; Leukocytes	1987
Three types of stereospecificity and the kinetic deuterium isotope effect in the oxidative deamination of dopamine as catalyzed by different amine oxidases. Biochemistry and cell biology = Biochimie et biologie cellulaire, 1988, Volume: 66, Issue:8 Topics: 3,4-Dihydroxyphenylacetic Acid; Amine Oxidase (Copper-Containing); Animals; Aorta; Benzylamine Oxidase; Cattle; Deuterium; Dopamine; Fabaceae; Kidney; Kinetics; Male; Mitochondria, Liver; Monoamine Oxidase; Oxidation-Reduction; Oxidoreductases Acting on CH-NH Group Donors; Plants; Plants, Medicinal; Rats; Rats, Inbred Strains; Stereoisomerism; Swine	1988
Aldehyde dehydrogenase activity in brain and liver of the rainbow trout (Salmo gairdneri Richardson). The Journal of experimental zoology, 1988, Volume: 247, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Brain; Cell Fractionation; Chromatography, High Pressure Liquid; Cytosol; Disulfiram; Glutamate Dehydrogenase; Hydrogen-Ion Concentration; Kinetics; L-Lactate Dehydrogenase; Liver; Magnesium; Male; Microsomes; Mitochondria; Rats; Rats, Inbred Strains; Salmonidae; Trout	1988
Assay of brain aldehyde dehydrogenase activity using high-performance liquid chromatography with electrochemical detection. Analytical biochemistry, 1986, Volume: 158, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Brain; Chromatography, High Pressure Liquid; Electrochemistry; Quality Control; Rats	1986
Chemical modification of human aldehyde dehydrogenase by physiological substrate. Biochimica et biophysica acta, 1987, Feb-25, Volume: 911, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Chemical Phenomena; Chemistry, Physical; Chloral Hydrate; Circular Dichroism; Humans; Isoenzymes; Kinetics; NAD; Phenylacetates	1987
Adducts of propiolaldehyde and 3,4-dihydroxyphenylacetaldehyde with human aldehyde dehydrogenase. Progress in clinical and biological research, 1985, Volume: 183 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehydes; Binding Sites; Humans; In Vitro Techniques; Kinetics; Phenylacetates; Structure-Activity Relationship	1985
Enzymology and subcellular localization of aldehyde oxidation in rat liver. Oxidation of 3,4-dihydroxyphenylacetaldehyde derived from dopamine to 3,4-dihydroxyphenylacetic acid. Biochemical pharmacology, 1981, Dec-15, Volume: 30, Issue:24 Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Oxidoreductases; Aldehyde Dehydrogenase; Aldehyde Oxidoreductases; Animals; Dopamine; Isoenzymes; Liver; Male; Oxidation-Reduction; Phenylacetates; Rats; Rats, Inbred Strains; Subcellular Fractions	1981
Human aldehyde dehydrogenase: 3,4-dihydroxyphenylaldehyde metabolizing isozymes. Progress in clinical and biological research, 1982, Volume: 114 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehyde Oxidoreductases; Brain; Humans; Isoenzymes; Kidney; Kinetics; Liver; Lung; Muscles; Myocardium; Organ Specificity; Phenylacetates; Spleen; Stomach; Substrate Specificity	1982
Confirmation of a dopamine metabolite in parkinsonian brain tissue by gas chromatography-mass spectrometry. Journal of chromatography, 1993, May-05, Volume: 614, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Brain; Dopamine; Gas Chromatography-Mass Spectrometry; Humans; Molecular Structure; Monoamine Oxidase; Parkinson Disease; Substantia Nigra	1993
An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration, 1995, Volume: 4, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Culture Techniques; Dopamine; Dopamine Uptake Inhibitors; gamma-Aminobutyric Acid; L-Lactate Dehydrogenase; Mesencephalon; Neostriatum; Nerve Endings; Parkinson Disease; PC12 Cells; Radioligand Assay; Rats; Synaptosomes	1995
Identification and determination of 3,4-dihydroxyphenylacetaldehyde, the dopamine metabolite in in vivo dialysate from rat striatum. Journal of neurochemistry, 1996, Volume: 66, Issue:4 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Dopamine; Male; Microdialysis; Neostriatum; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity	1996
The effect of N-methyl-norsalsolinol on monoamine oxidase of the rat caudate nucleus in vitro. Neurochemistry international, 1996, Volume: 28, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucleus; Dopamine; Female; In Vitro Techniques; Isoenzymes; Isoquinolines; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidation-Reduction; Rats; Rats, Wistar; Tetrahydroisoquinolines	1996
Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography. Analytical biochemistry, 1999, Aug-15, Volume: 273, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Calibration; Catechols; Chromatography, High Pressure Liquid; Dopamine; Humans; Microchemistry; Monoamine Oxidase; Norepinephrine	1999
Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. Journal of neuroscience research, 2000, May-15, Volume: 60, Issue:4 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Differentiation; Cell Line; Cell Survival; Dopamine; Dose-Response Relationship, Drug; Electron Transport; Glucose; Homovanillic Acid; Humans; L-Lactate Dehydrogenase; Mitochondria; Nerve Growth Factor; Neurons; Neurotoxins; Oxidation-Reduction; PC12 Cells; Phenylethyl Alcohol; Rats; Rotenone; Stress, Physiological; Uncoupling Agents	2000
3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain research, 2000, Jun-23, Volume: 868, Issue:2 Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Dopamine; Energy Metabolism; Enzyme Inhibitors; Estrogens, Non-Steroidal; Fluorenes; Hydantoins; Isoflavones; Mitochondria; Neurons; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; PC12 Cells; Phenylethyl Alcohol; Rats; Rotenone	2000
Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free radical biology & medicine, 2001, Apr-15, Volume: 30, Issue:8 Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Aminobenzoic Acid; Aminobenzoates; Animals; Aristolochic Acids; Cell Death; Cell Differentiation; Cyclosporine; Dopamine; Dopamine Antagonists; Enzyme Inhibitors; Ion Channels; Male; Membrane Proteins; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Nerve Growth Factor; para-Aminobenzoates; Parkinson Disease; PC12 Cells; Phenanthrenes; Rats; Rats, Inbred F344; Respiration; Rotenone; Trifluoperazine; Uncoupling Agents	2001
Biogenic aldehyde(s) derived from the action of monoamine oxidase may mediate the antidipsotropic effect of daidzin. Chemico-biological interactions, 2001, Jan-30, Volume: 130-132, Issue:1-3 Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Deterrents; Alcohol Drinking; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Aldehydes; Animals; Chlorocebus aethiops; Cricetinae; Dopamine; Enzyme Inhibitors; Humans; Hydroxyindoleacetic Acid; In Vitro Techniques; Isoflavones; Mesocricetus; Mitochondria, Liver; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rats; Serotonin	2001
3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. Brain research. Molecular brain research, 2001, Sep-10, Volume: 93, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aldehydes; Brain; Catechols; Humans; Hydrogen Peroxide; Hydroxyl Radical; Male; Nerve Degeneration; Parkinson Disease; Spectrophotometry, Atomic	2001
Oxidative metabolite of dopamine, 3,4-dihydroxyphenylacetaldehyde, induces dopamine release from PC12 cells by a Ca2+-independent mechanism. Brain research, 2002, Mar-22, Volume: 931, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Calcium; Calcium Channel Blockers; Dopamine; L-Lactate Dehydrogenase; Nifedipine; Oxidation-Reduction; Parkinson Disease; PC12 Cells; Rats	2002
Convenient syntheses of biogenic aldehydes, 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde. Bioorganic chemistry, 2003, Volume: 31, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Catechols; Hydrolysis; Hydroxyl Radical; Indicators and Reagents	2003
The oxidation of 3,4-dihydroxyphenylacetaldehyde. Biochimica et biophysica acta, 1959, Volume: 35 Topics: 3,4-Dihydroxyphenylacetic Acid; Acetaldehyde; Oxidation-Reduction	1959
3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain research, 2003, Nov-07, Volume: 989, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glial Fibrillary Acidic Protein; Homovanillic Acid; Immunohistochemistry; Male; Neurons; Parkinson Disease; Phenylethyl Alcohol; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase; Ventral Tegmental Area	2003
Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones. Journal of neuroscience research, 2004, Feb-01, Volume: 75, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Disulfiram; Dopamine; Dopamine Agents; Enzyme Inhibitors; Levodopa; Male; Neurons; Rats; Rats, Sprague-Dawley; Time Factors	2004
Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation. Neurotoxicology, 2004, Volume: 25, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Catecholamines; Cell Line, Tumor; Cell Survival; Disulfiram; Dopamine; Humans; Neuroblastoma	2004
[Assessment of the in vitro and in vivo toxicity of 3,4-dihydroxyphenylacetaldehyde (DOPAL)]. Annales pharmaceutiques francaises, 2004, Volume: 62, Issue:5 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Levodopa; Male; Neostriatum; Rats; Rats, Sprague-Dawley	2004
Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. Neurotoxicology, 2007, Volume: 28, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehyde Reductase; Aldehydes; Animals; Chromatography, High Pressure Liquid; Dopamine; Half-Life; Humans; Mitochondria; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Sprague-Dawley	2007
Dopamine release in the nucleus accumbens (shell) of two lines of rats selectively bred to prefer or avoid ethanol. European journal of pharmacology, 2007, Nov-14, Volume: 573, Issue:1-3 Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Drinking; Alcoholism; Anesthesia, Inhalation; Animals; Breeding; Chromatography, High Pressure Liquid; Dextroamphetamine; Dopamine; Female; Genetic Predisposition to Disease; Homovanillic Acid; Hydroxyindoleacetic Acid; Isoflurane; Male; Microdialysis; Nucleus Accumbens; Potassium Chloride; Rats; Rats, Inbred Strains; Serotonin; Stereotaxic Techniques	2007
Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate. Chemical research in toxicology, 2007, Volume: 20, Issue:10 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Animals; Corpus Striatum; Cross-Linking Reagents; Dopamine; Dose-Response Relationship, Drug; Drug Antagonism; Enzyme Inhibitors; Lipid Peroxidation; Malondialdehyde; Oxidative Stress; Rats; Rats, Sprague-Dawley; Synaptosomes	2007
Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chemical research in toxicology, 2009, Volume: 22, Issue:5 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Reductase; Aldehydes; Animals; Dopamine; Lipid Peroxidation; Malondialdehyde; Oxidation-Reduction; Oxidative Stress; PC12 Cells; Phenylethyl Alcohol; Rats	2009
Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Chemical research in toxicology, 2009, Volume: 22, Issue:7 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Animals; Catechols; Cattle; Cross-Linking Reagents; Dopamine; Glyceraldehyde-3-Phosphate Dehydrogenases; Mice; Mitochondria, Liver; Rats; Serum Albumin, Bovine	2009
Multiple roles of the active site lysine of Dopa decarboxylase. Archives of biochemistry and biophysics, 2009, Aug-15, Volume: 488, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Alanine; Amino Acid Substitution; Ammonia; Animals; Binding Sites; Catalysis; Deamination; Decarboxylation; Dopa Decarboxylase; Dopamine; Hydrogen Bonding; Hydrolysis; Kidney; Kinetics; Levodopa; Lysine; Models, Chemical; Molecular Structure; Oxidation-Reduction; Protein Binding; Protein Conformation; Pyridoxal Phosphate; Structure-Activity Relationship; Swine	2009
Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde. Clinical chemistry, 2010, Volume: 56, Issue:5 Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Chromatography, Liquid; Droxidopa; Drug Contamination; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Parkinson Disease	2010
Catechols in post-mortem brain of patients with Parkinson disease. European journal of neurology, 2011, Volume: 18, Issue:5 Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Brain Chemistry; Dopamine; Female; Humans; Male; Parkinson Disease; Putamen	2011
The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PloS one, 2010, Dec-13, Volume: 5, Issue:12 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Dopamine; Glial Fibrillary Acidic Protein; Immunohistochemistry; Male; Microglia; Neurons; Parkinson Disease; Phenotype; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase	2010
From L-dopa to dihydroxyphenylacetaldehyde: a toxic biochemical pathway plays a vital physiological function in insects. PloS one, 2011, Jan-24, Volume: 6, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Dopa Decarboxylase; Drosophila melanogaster; Insect Proteins; Insecta; Levodopa	2011
Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite. Neurotoxicology, 2011, Volume: 32, Issue:4 Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenal Glands; Animals; Blotting, Western; Cell Line, Tumor; Cell Survival; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Kinetics; Levodopa; Protein Processing, Post-Translational; Rats; Time Factors; Tyrosine 3-Monooxygenase	2011
Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. The Journal of biological chemistry, 2011, Jul-29, Volume: 286, Issue:30 Topics: 3,4-Dihydroxyphenylacetic Acid; Benzoquinones; Cyclooxygenase 2; Free Radicals; Humans; Oxidation-Reduction; Parkinson Disease	2011
Natural toxin implicated as triggering Parkinson's disease. Pakistan journal of biological sciences : PJBS, 2011, Feb-01, Volume: 14, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Humans; Neurons; Neurotoxins; Parkinson Disease	2011
Identification of aldehyde dehydrogenase 1A1 modulators using virtual screening. Journal of enzyme inhibition and medicinal chemistry, 2013, Volume: 28, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Dehydrogenase, Mitochondrial; Benzamides; Benzodioxoles; Binding Sites; Case-Control Studies; Enzyme Activation; Gene Expression Regulation, Enzymologic; Humans; Ligands; Molecular Docking Simulation; Parkinson Disease; Retinal Dehydrogenase; Small Molecule Libraries; Substantia Nigra; User-Computer Interface	2013
Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PloS one, 2012, Volume: 7, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Body Weight; Cognition Disorders; Cytosol; Disease Models, Animal; Dopamine; Female; Genotype; Male; Mice; Mice, Transgenic; Mitochondria; NAD; Neurodegenerative Diseases; Neurons; Parkinson Disease; Time Factors; Tyrosine 3-Monooxygenase	2012
Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity. Brain research, 2012, Sep-20, Volume: 1474 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Catechols; Cell Line; Chromatography, High Pressure Liquid; Dopaminergic Neurons; Flow Cytometry; Humans; Parkinson Disease; Structure-Activity Relationship; Tyrosine 3-Monooxygenase	2012
Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease. Journal of neurochemistry, 2012, Volume: 123, Issue:6 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cytoplasmic Vesicles; Dopamine; Neurons; Parkinsonian Disorders; PC12 Cells; Rats	2012
Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, Jan-08, Volume: 110, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Benomyl; Dopaminergic Neurons; Flow Cytometry; Fungicides, Industrial; Humans; Logistic Models; Mesencephalon; Mitochondria; Nerve Degeneration; Odds Ratio; Parkinson Disease; Rats; Zebrafish	2013
Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. Journal of neurochemistry, 2013, Volume: 126, Issue:5 Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Dehydrogenase, Mitochondrial; Animals; Brain Chemistry; Catechols; Dihydroxyphenylalanine; Dopamine; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Parkinson Disease; Putamen; Retinal Dehydrogenase; Vesicular Monoamine Transport Proteins	2013
Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein. Neuroscience letters, 2014, May-21, Volume: 569 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Antioxidants; Ascorbic Acid; Cations, Divalent; Chelating Agents; Copper; Dopamine; Edetic Acid; Humans; Iron; Manganese; PC12 Cells; Phenylethyl Alcohol; Protein Aggregates; Protein Multimerization; Rats	2014
Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease. Chemical research in toxicology, 2014, Aug-18, Volume: 27, Issue:8 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehydes; Animals; Antifungal Agents; Benomyl; Cell Line; Enzyme Inhibitors; Humans; Lipid Peroxidation; Mice; Parkinson Disease; PC12 Cells; Rats	2014
The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein. Neuroscience letters, 2015, Mar-17, Volume: 590 Topics: 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; alpha-Synuclein; Animals; Dopamine; Hydroxyindoleacetic Acid; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; PC12 Cells; Polymerization; Rats; Serotonin	2015
Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy. Parkinsonism & related disorders, 2015, Volume: 21, Issue:6 Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Aldehyde Dehydrogenase; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Female; Frontal Lobe; Humans; Male; Methoxyhydroxyphenylglycol; Multiple System Atrophy; Neurons; Norepinephrine; Parkinson Disease	2015
Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). The Journal of biological chemistry, 2015, Nov-13, Volume: 290, Issue:46 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Animals; Cell Membrane; Dopamine; Dopaminergic Neurons; Humans; Lysine; Membrane Lipids; Oxidation-Reduction; Parkinson Disease; Rats; Schiff Bases; Substantia Nigra	2015
Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells. The Journal of pharmacology and experimental therapeutics, 2016, Volume: 356, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; PC12 Cells; Rats	2016
DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells. Autonomic neuroscience : basic & clinical, 2016, Volume: 194 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Catecholamines; Cell Line; Dose-Response Relationship, Drug; Glioblastoma; Humans; Mutation; Neuroglia; PC12 Cells; Protein Aggregates; Rats; Subcellular Fractions; Time Factors	2016
Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of α-Synuclein. Angewandte Chemie (International ed. in English), 2016, 06-20, Volume: 55, Issue:26 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Cross-Linking Reagents; Humans; Limit of Detection; Pyrroles	2016
3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells. Neurochemical research, 2016, Volume: 41, Issue:9 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopamine Agents; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidation-Reduction; Parkinson Disease; PC12 Cells; Phenylethyl Alcohol; Rats	2016
Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite. Chemical research in toxicology, 2016, 07-18, Volume: 29, Issue:7 Topics: 3,4-Dihydroxyphenylacetic Acid; Amines; Animals; Antioxidants; Dopamine; Hydrogen-Ion Concentration	2016
DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Scientific reports, 2017, 01-13, Volume: 7 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Biological Transport; Cell Line; Cell Membrane; Humans; Magnetic Resonance Spectroscopy; Mice; Neurons; Permeability; Protein Aggregates; Protein Aggregation, Pathological; Protein Binding; Protein Multimerization; Synaptic Vesicles; Tandem Mass Spectrometry	2017
Superoxide is the critical driver of DOPAL autoxidation, lysyl adduct formation, and crosslinking of α-synuclein. Biochemical and biophysical research communications, 2017, May-27, Volume: 487, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Binding Sites; Cross-Linking Reagents; Enzyme Activation; Lysine; Oxidation-Reduction; Oxygen; Protein Binding; Pyrroles; Reactive Oxygen Species; Superoxide Dismutase	2017
Neurochemical evidence that cocaine- and amphetamine-regulated transcript (CART) 55-102 peptide modulates the dopaminergic reward system by decreasing the dopamine release in the mouse nucleus accumbens. Brain research bulletin, 2017, Volume: 134 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cocaine; Dopamine; Dopamine Uptake Inhibitors; Electric Stimulation; Extracellular Space; Homovanillic Acid; Humans; Male; Mice; Nerve Tissue Proteins; Norepinephrine; Nucleus Accumbens; Peptide Fragments; Phenylethyl Alcohol; Reward; Tissue Culture Techniques	2017
A Systems Model of Parkinson's Disease Using Biochemical Systems Theory. Omics : a journal of integrative biology, 2017, Volume: 21, Issue:8 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Biomarkers; Brain; Cell Death; Computer Simulation; Disease Progression; Dopamine; Dopaminergic Neurons; Gene Expression Regulation; Humans; Models, Statistical; Neurofibrillary Tangles; Parkinson Disease; Reactive Oxygen Species; Signal Transduction; Stochastic Processes; Systems Theory; tau Proteins; Ubiquitin-Protein Ligases	2017
Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde. Biochemical and biophysical research communications, 2017, 10-14, Volume: 492, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Enzyme Induction; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Parkinson Disease; Protein Aggregates; Rabbits; Rats	2017
Pleiotropic neuropathological and biochemical alterations associated with Myo5a mutation in a rat Model. Brain research, 2018, 01-15, Volume: 1679 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Central Nervous System; Disease Models, Animal; Electron Transport Chain Complex Proteins; Heredodegenerative Disorders, Nervous System; Microscopy, Electron, Transmission; Mutation; Myosin Heavy Chains; Myosin Type V; Phosphorylation; Rats; Rats, Mutant Strains; tau Proteins	2018
PCB95 and PCB153 change dopamine levels and turn-over in PC12 cells. Toxicology, 2018, 02-01, Volume: 394 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Male; Neurotoxicity Syndromes; PC12 Cells; Polychlorinated Biphenyls; Rats	2018
Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein. Biochemistry, 2018, 03-06, Volume: 57, Issue:9 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Cross-Linking Reagents; Humans; Isoindoles; Models, Molecular; Neurons; Oxidation-Reduction; Parkinson Disease	2018
3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by The Journal of pharmacology and experimental therapeutics, 2018, Volume: 366, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Humans; Intracellular Space; Oxidation-Reduction; PC12 Cells; Protein Multimerization; Protein Structure, Quaternary; Proteins; Proteolysis; Quinones; Rats	2018
Biochemical characterization of the catecholaldehyde reactivity of L-carnosine and its therapeutic potential in human myocardium. Amino acids, 2019, Volume: 51, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aldehydes; Carnosine; Catechols; Cysteine; Glutathione; Humans; Middle Aged; Mitochondria; Myocardium; Oxidation-Reduction	2019
Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde. ACS chemical neuroscience, 2019, 01-16, Volume: 10, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylation; alpha-Synuclein; Dopamine; Dopaminergic Neurons; Humans; Membrane Lipids; Mutation; Oxidation-Reduction; Parkinson Disease; Protein Multimerization; Protein Processing, Post-Translational	2019
Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy. European journal of pharmacology, 2019, Feb-15, Volume: 845 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; alpha-Synuclein; Animals; Indans; Neuroprotective Agents; Parkinson Disease; PC12 Cells; Rats	2019
Mechanism-based tuning of insect 3,4-dihydroxyphenylacetaldehyde synthase for synthetic bioproduction of benzylisoquinoline alkaloids. Nature communications, 2019, 05-01, Volume: 10, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acid Motifs; Animals; Aromatic-L-Amino-Acid Decarboxylases; Bombyx; Dopamine; Escherichia coli; Insect Proteins; Metabolic Engineering; Recombinant Proteins; Structure-Activity Relationship; Tetrahydropapaveroline	2019
3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing The Journal of pharmacology and experimental therapeutics, 2020, Volume: 372, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; alpha-Synuclein; Antioxidants; Cell Line; Copper; Dopamine; Humans; Monoamine Oxidase; Monophenol Monooxygenase; Oligodendroglia; Oxidation-Reduction; Parkinson Disease; Protein Binding; Protein Conformation; Tolcapone	2020
Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson's disease through mitochondrial dysfunction. PLoS genetics, 2020, Volume: 16, Issue:6 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Brain; Cell Line; Cell Line, Tumor; Cohort Studies; COUP Transcription Factor II; Datasets as Topic; Disease Models, Animal; Disease Progression; Dopaminergic Neurons; Female; Humans; Male; Mice; Mice, Knockout; Mitochondria; Oxidative Stress; Parkinson Disease; Primary Cell Culture; Rats; RNA-Seq; Up-Regulation	2020
A novel LC-MS/MS method for quantification of unstable endogenous 3,4-dihydroxyphenylacetaldehyde in rat brain after chemical derivatization. Journal of pharmaceutical and biomedical analysis, 2021, Feb-20, Volume: 195 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, Liquid; Corpus Striatum; Rats; Tandem Mass Spectrometry	2021
Parkinson-like early autonomic dysfunction induced by vagal application of DOPAL in rats. CNS neuroscience & therapeutics, 2021, Volume: 27, Issue:5 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Autonomic Nervous System Diseases; Baroreflex; Blood Pressure; Electrocardiography; Hypotension, Orthostatic; Male; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Nodose Ganglion; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Vagus Nerve	2021
Enhanced tyrosine hydroxylase activity induces oxidative stress, causes accumulation of autotoxic catecholamine metabolites, and augments amphetamine effects in vivo. Journal of neurochemistry, 2021, Volume: 158, Issue:4 Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Catecholamines; Central Nervous System Stimulants; Dopamine; Female; Gene Dosage; Glutathione; Humans; Hydrogen Peroxide; Male; Mice; Mice, Transgenic; Neurons; Oxidative Stress; Tyrosine 3-Monooxygenase	2021
Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC. International journal of molecular sciences, 2021, Jun-02, Volume: 22, Issue:11 Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Cell Proliferation; Dopamine; Dopaminergic Neurons; Humans; Oxidative Stress; Parkinson Disease; Phenylethyl Alcohol; Protein Aggregation, Pathological; Protein Multimerization	2021
In vitro inhibition of glutathione-S-transferase by dopamine and its metabolites, 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetic acid. Neurotoxicology, 2021, Volume: 86 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Line; Dopamine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Glutathione Transferase; Horses; Rats	2021
Characterization of Catecholaldehyde Adducts with Carnosine and l-Cysteine Reveals Their Potential as Biomarkers of Catecholaminergic Stress. Chemical research in toxicology, 2021, 10-18, Volume: 34, Issue:10 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Carnosine; Catechols; Cell Line, Tumor; Cysteine; Humans; Mice; Mice, Inbred C57BL; Molecular Structure; Monoamine Oxidase	2021
Oxidative Transformations of 3,4-Dihydroxyphenylacetaldehyde Generate Potential Reactive Intermediates as Causative Agents for Its Neurotoxicity. International journal of molecular sciences, 2021, Oct-29, Volume: 22, Issue:21 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Neurotoxicity Syndromes; Oxidation-Reduction; Parkinson Disease	2021